<div><p><b>Background: </b>New therapeutic alternatives to corticosteroids in severe alcohol-associated hepatitis (SAH) is unmet need. Fecal microbiota transplantation (FMT) has been proposed as it targets well-established pathophysiological pathway but, data is scarce and many unanswered questions remain. One of the principal tools for personalized management of SAH is selection of patients whose potential to benefit from FMT is increased based on their pre-FMT gut-microbiome analysis.</p>

<div><p><strong>Background</strong>: Systemic inflammation is known as a major role in pathogenesis of acute-on-chronic liver failure (ACLF) from cross-sectional studies, but its detailed impacts on the dynamic trajectory of this disease from the absence of organ dysfunction (OD) to onset of OD, organ failure (OF) and eventual ACLF remains poorly understood due to challenges in collecting data and samples from individuals. Multinomial and ordinal regression analyses are useful tools to circumvent the limitation intrinsic to cross-sectional studies in cirrhosis.

<div><p><b>Background: </b>Primary sclerosing cholangitis (PSC) is marked by inflammation and progressive biliary fibrosis, which can lead to cirrhosis and its complications. Cholangiocytes activated by transforming growth factor-𝛽 (TGF𝛽) signal to immune cells and activate hepatic myofibroblasts to deposit the extracellular matrix. Our previous data suggest that TGF𝛽-mediated transcriptomic changes in cholangiocytes may occur through runt-related transcription factors (RUNX).

<div><p><b>Background:</p> </b><p>Lubiprostone has been shown to improve intestinal permeability. We aimed to assess the safety and efficacy of lubiprostone in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).</p>

<div><p><strong><b>Background:</strong> </b></p>

<div><p><b>Background: </b>Physical frailty and sarcopenia are related but not fully overlapping, and links to outcomes and health care utilization in liver cirrhosis. Physical frailty may be assessed with Liver Frailty Index (LFI) or Short Performance Physical Battery (SPPB), and sarcopenia is typically assessed by measuring muscle size using imaging.</p>

<div><p><strong>Background</strong>: The American Association for the Study of Liver Diseases has stated that fostering a “supportive environment for transsexual individuals seeking hepatology care” is an important goal. However, the landscape of transgender patients with cirrhosis is largely unknown. We aimed to assess the clinical characteristics of transgender patients with cirrhosis and quantify their outcomes. </p>

<div><p><strong><b>Background:</strong> </b></p>
<p>Point-of-care echocardiography (POC-Echo) can be used to evaluate Cirrhotic Cardiomyopathy (CCM) and inferior vena cava (IVC) dynamics. The impact of cardiac function and IVC dynamics on cirrhosis progression towards refractory ascites and HRS-AKI is yet to be defined. This study aims to evaluate the utility of CCM markers and IVC changes, assessed by POC-Echo, in predicting adverse outcomes in patients with cirrhosis and ascites.</p>
<p></p>

<div><p><b>Background:</p> </b><p>A-LiNK (Autoimmune Liver disease Network for Kids) is a collaborative, multi-center learning health network uniting patients, parents, clinicians, researchers, and stakeholders to address gaps in care for children with Autoimmune Liver Disease. We seek to define predictors of optimal outcomes and determine current practices in Autoimmune Hepatitis (AIH).</p>

<div><p><strong><b>Background:</strong> </b>Metabolic dysfunction-associated steatohepatitis (MASH) diagnosis and scoring depend on invasive liver biopsies by measuring metabolic dysfunction-associated steatotic liver disease (MASLD) activity score (NAS) and fibrosis score. However, a quantitative estimation of the combined effect of clinically available laboratory measures and transient elastography parameters (controlled attenuation parameter [CAP] and liver stiffness score [LSM]) as a screening / diagnostic test for advanced MASH has been suggested.